GlassScriptPhysician profile
Marvin A Lipsky
NPI 1932198942
$3,210.67
in general payments reported to CMS, 2019-2025
21 companies · $236 in 2025
The $236 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $312 · 2021: $309 · 2022: $449 · 2023: $658 · 2024: $400 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,282 · Education: $11.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,281.75 |
| Education | $11.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $949.86 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $631.98 | 2019-2024 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $581.42 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $395.95 | 2021-2024 | Zeposia |
| Pfizer INC. | $145.03 | 2019-2025 | |
| Gilead Sciences, INC. | $74.48 | 2020-2025 | |
| Ardelyx, INC. | $51.00 | 2025 | Ibsrela |
| Janssen Biotech, INC. | $48.23 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $41.26 | 2021 | |
| Medtronic, INC. | $38.60 | 2024 | Gi Genius |
| Lilly USA, LLC | $34.73 | 2023 | |
| Merck Sharp & Dohme LLC | $32.25 | 2023 | Dificid |
| Aimmune Therapeutics, INC. | $31.96 | 2023-2024 | |
| Genzyme Corporation | $31.42 | 2022-2025 | |
| Redhill Biopharma INC. | $27.66 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $27.48 | 2019-2022 | |
| Celltrion USA INC. | $17.22 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $14.32 | 2021 | |
| Qol Medical, LLC | $12.78 | 2019 | |
| Endo Pharmaceuticals INC. | $12.05 | 2019 | |
| Allergan, INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Lipsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.